{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:16:43Z","timestamp":1788362203472,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Infective endocarditis (IE) is associated with an in-hospital mortality rate of 15\u201330%. Standard treatment requires 2 to 6 weeks of intravenous (IV) antibiotic therapy, resulting in prolonged hospitalization with its attendant risks, including catheter-related complications, increased length of stay, and cost. This review summarizes the current evidence, eligibility criteria, antibiotic regimen selection, and practical aspects of partial oral antibiotic therapy (POAT) for IE. Oral treatment is already recommended for right-sided Staphylococcus aureus IE and IE caused by selected atypical pathogens (e.g., Brucella spp., Coxiella burnetii, Bartonella spp., and Tropheryma whipplei). The landmark Partial Oral Treatment of Endocarditis trial (2019) demonstrated the non-inferiority of POAT\u2014initiated after at least 10 days of IV therapy\u2014versus continued IV treatment for left-sided IE caused by streptococci, Enterococcus faecalis, S. aureus, or coagulase-negative staphylococci. Long-term follow-up at 5.4 years demonstrated lower all-cause mortality in the POAT group. The 2023 European Society of Cardiology Guidelines now formally endorse POAT for selected patients fulfilling strict criteria. Despite robust evidence, POAT is currently implemented in fewer than half of eligible patients. These findings have since been corroborated by the WikiGuidelines Group consensus statement and the French Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise\u2013Association pour l\u2019\u00c9tude et la Pr\u00e9vention de l\u2019Endocardite Infectieuse position statement, and extended by real-world evidence (the ENDO-ORAL study) suggesting that carefully selected patients falling outside strict trial-based eligibility criteria may also benefit from oral step-down therapy. In appropriately selected and clinically stable patients, POAT is supported by randomized and real-world evidence as an alternative to prolonged IV therapy. Strict adherence to eligibility criteria, appropriate antibiotic selection based on pathogen susceptibility, and close clinical follow-up are essential to optimize outcomes.<\/jats:p>","DOI":"10.3390\/pathogens15090924","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:35:29Z","timestamp":1788359729000},"page":"924","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Partial Oral Antibiotic Therapy for Infective Endocarditis: A Practical Review of Current Evidence and Guidelines"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2660-5476","authenticated-orcid":false,"given":"Thomas","family":"Roland","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, CHU HELORA (Centre Hospitalier Universitaire Helora), 7000 Mons, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Cyr","family":"Yombi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis","volume":"36","author":"Habib","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"ref_3","first-page":"2485","article-title":"Oral antibiotics for infective endocarditis: A clinical review","volume":"75","author":"Brown","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus Intravenous Antibiotics for Bone and Joint Infection","volume":"380","author":"Li","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra2213296","article-title":"Prevention of Central Line\u2013Associated Bloodstream Infections","volume":"389","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/598930","article-title":"Health-Related Quality of Life and Posttraumatic Stress Disorder among Survivors of Left-Sided Native Valve Endocarditis","volume":"48","author":"Verhagen","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1179\/acb.2009.034","article-title":"Risk Factors Predicting Later Functional Decline in Older Hospitalized Patients","volume":"64","author":"Schoevaerdts","year":"2009","journal-title":"Acta Clin. Belg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2024.06.053","article-title":"Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial","volume":"84","author":"Ostergaard","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.medmal.2014.05.001","article-title":"Outpatient parenteral antimicrobial therapy for infective endocarditis: A cost-effective strategy","volume":"44","author":"Lacroix","year":"2014","journal-title":"M\u00e9d. Et. Mal. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1093\/eurheartj\/ehad715","article-title":"Clinical implementation of partial oral treatment in infective endocarditis: The Danish POETry study","volume":"44","author":"Hjulmand","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC Guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e003016","DOI":"10.1161\/JAHA.115.003016","article-title":"Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis","volume":"5","author":"Park","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1093\/eurheartj\/ehz620","article-title":"Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO registry","volume":"40","author":"Habib","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/eurheartj\/ehz175","article-title":"Staphylococcus aureus endocarditis: Distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves","volume":"40","author":"Liesenborghs","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10096-018-3401-9","article-title":"Factors associated with unfavorable outcome in a multicenter audit of 100 infective endocarditis","volume":"38","author":"Chirio","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Intern Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40119-019-00148-4","article-title":"Current Evidence on Oral Antibiotics for Infective Endocarditis: A Narrative Review","volume":"8","author":"Kobayashi","year":"2019","journal-title":"Cardiol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/321814","article-title":"Patient Selection Criteria and Management Guidelines for Outpatient Parenteral Antibiotic Therapy for Native Valve Infective Endocarditis","volume":"33","author":"Andrews","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CMR.14.1.177-207.2001","article-title":"Endocarditis Due to Rare and Fastidious Bacteria","volume":"14","author":"Brouqui","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1378\/chest.74.2.224","article-title":"Bacterial Endocarditis on a Prosthetic Valve","volume":"74","author":"Lidji","year":"1978","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the Treatment of Multidrug-Resistant, Gram-Positive Infections: Experience from a Compassionate-Use Program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkl219","article-title":"Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence","volume":"58","author":"Falagas","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijantimicag.2019.06.006","article-title":"High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis","volume":"54","author":"Gouriet","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/clinids\/13.Supplement_2.S160","article-title":"Antibiotic Management of Outpatients with Endocarditis Due to Penicillin-Susceptible Streptococci","volume":"13","author":"Stamboulian","year":"1991","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.medmal.2011.08.003","article-title":"Audit of antibiotic therapy used in 66 cases of endocarditis","volume":"41","author":"Demonchy","year":"2011","journal-title":"M\u00e9d. Et. Mal. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cmi.2016.04.003","article-title":"Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients","volume":"22","author":"Mzabi","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Al-Omari, A., Cameron, D.W., Lee, C., and Corrales-Medina, V.F. (2014). Oral antibiotic therapy for the treatment of infective endocarditis: A systematic review. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-140"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e075297","DOI":"10.1136\/bmj-2023-075297","article-title":"Sustainable practice: Prescribing oral over intravenous medications","volume":"383","author":"Eii","year":"2023","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Okazaki, F., Tsuji, Y., Seto, Y., Ogami, C., Yamamoto, Y., and To, H. (2019). Effects of a rifampicin pre-treatment on linezolid pharmacokinetics. PLoS ONE, 14.","DOI":"10.1101\/572610"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0091270010366445","article-title":"Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism","volume":"51","author":"Gandelman","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMc2114046","article-title":"Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial","volume":"386","author":"Wiingaard","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","first-page":"ofad649","article-title":"Real-world Application of Oral Therapy for Infective Endocarditis: A Multicenter Retrospective Cohort Study","volume":"11","author":"Freling","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1093\/cid\/ciaf452","article-title":"Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study","volume":"82","author":"Rallet","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12471-020-01490-2","article-title":"Retrospective analysis of endocarditis patients to investigate the eligibility for oral antibiotic treatment in routine daily practice","volume":"29","author":"Vroon","year":"2021","journal-title":"Neth. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"ofae166","DOI":"10.1093\/ofid\/ofae166","article-title":"Shared Decision-Making for Partial Oral Antibiotic Treatment of Infective Endocarditis: A Case Series","volume":"11","author":"Castillo","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"ofaf625","DOI":"10.1093\/ofid\/ofaf625","article-title":"Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study","volume":"12","author":"Collis","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"dlaf032","DOI":"10.1093\/jacamr\/dlaf032","article-title":"Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: A case series and literature review of real-world data","volume":"7","author":"Lundgren","year":"2025","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/cid\/ciad168","article-title":"Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy","volume":"77","author":"Bock","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"110718","DOI":"10.1016\/j.jpsychores.2022.110718","article-title":"The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial","volume":"154","author":"Bundgaard","year":"2022","journal-title":"J. Psychosom. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"ofaf580","DOI":"10.1093\/ofid\/ofaf580","article-title":"Partial Oral Therapy for Infective Endocarditis Among Adult Infectious Diseases Physicians in the United States: An Emerging Infections Network Survey","volume":"12","author":"McHugh","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_43","first-page":"105034","article-title":"ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES). Early oral switch therapy for infective endocarditis: An international cross-sectional survey on current use in clinical practice","volume":"2","author":"Hornuss","year":"2025","journal-title":"CMI Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00508-020-01614-z","article-title":"Partial oral antibiotic therapy is non-inferior to intravenous therapy in non-critically ill patients with infective endocarditis: Review and meta-analysis","volume":"132","author":"Rezar","year":"2020","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_45","first-page":"CD009880","article-title":"A comparison of different antibiotic regimens for the treatment of infective endocarditis","volume":"5","author":"Dayer","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amjmed.2021.10.007","article-title":"Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review","volume":"135","author":"Holtom","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cmi.2023.04.030","article-title":"Choosing patients over placebos: Oral transitional therapy vs. IV-only therapy for bacteraemia and infective endocarditis","volume":"29","author":"Phillips","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Barda, B., Schindler, C., Bernasconi, E., and Bongiovanni, M. (2024). Breaking the Dogma of Intravenous Treatment for Infective Endocarditis: A Systematic Review and Meta-Analysis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247518"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/cid\/ciae476","article-title":"Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials","volume":"80","author":"Mourad","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1473-3099(23)00756-9","article-title":"Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): An international, open-label, parallel-group, randomised, controlled, non-inferiority trial","volume":"24","author":"Kaasch","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2326366","DOI":"10.1001\/jamanetworkopen.2023.26366","article-title":"Guidelines for Diagnosis and Management of Infective Endocarditis in Adults: A WikiGuidelines Group Consensus Statement","volume":"6","author":"McDonald","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"105011","DOI":"10.1016\/j.idnow.2024.105011","article-title":"Antibiotic therapy and prophylaxis of infective endocarditis\u2014A SPILF-AEPEI position statement on the ESC 2023 guidelines","volume":"55","author":"Bonnet","year":"2025","journal-title":"Infect. Dis. Now."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cpt197620198","article-title":"Dicloxacillin and cloxacillin: Pharmacokinetics in healthy and hemodialysis subjects","volume":"20","author":"Nauta","year":"1976","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01833876","article-title":"Dicloxacillin and flucloxacillin: Pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration","volume":"23","author":"Espersen","year":"1995","journal-title":"Infection"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1161\/CIR.0000000000001187","article-title":"Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association","volume":"149","author":"Baddour","year":"2024","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/eurheartj\/ehae127","article-title":"Cardiac implantable electronic devices and bloodstream infections: Management and outcomes","volume":"45","author":"Demarchi","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e033540","DOI":"10.1136\/bmjopen-2019-033540","article-title":"Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): A protocol for two open-label randomised controlled trials","volume":"10","author":"Lemaignen","year":"2020","journal-title":"BMJ Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40121-025-01110-9","article-title":"Oral vs. Outpatient Parenteral Antimicrobial Treatment for Infective Endocarditis: Study Protocol for the Spanish OraPAT-IE GAMES Trial","volume":"14","author":"Cuervo","year":"2025","journal-title":"Infect. Dis. Ther."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/9\/924\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:44:22Z","timestamp":1788360262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/9\/924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pathogens15090924"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15090924","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}